Ionis Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Ionis Pharmaceuticals has a total shareholder equity of $662.5M and total debt of $1.8B, which brings its debt-to-equity ratio to 275.7%. Its total assets and total liabilities are $3.1B and $2.4B respectively.
Key information
275.7%
Debt to equity ratio
US$1.83b
Debt
| Interest coverage ratio | n/a |
| Cash | US$2.49b |
| Equity | US$662.47m |
| Total liabilities | US$2.42b |
| Total assets | US$3.08b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ISI's short term assets ($2.7B) exceed its short term liabilities ($304.6M).
Long Term Liabilities: ISI's short term assets ($2.7B) exceed its long term liabilities ($2.1B).
Debt to Equity History and Analysis
Debt Level: ISI has more cash than its total debt.
Reducing Debt: ISI's debt to equity ratio has increased from 43.8% to 275.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ISI has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ISI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.